Ledipasvir

雷迪帕韦

Report date: 2026/04/14 20:00:15
NME

Base Information

Drug NameLedipasvir
Drug Alias Nameledipasvir来帕司韦ledipasvirum来迪派韦GS-5885
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNonstructural protein 5A inhibitors
TargetsNonstructural protein 5A
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Liver CirrhosisCarcinoma, Hepatocellular +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Front Pharmaceutical Co Ltd
Inactive CompaniesGilead Sciences IncTanta UniversityNational Hepatology & Tropical Medicine Research Institute +[7] 
Active IndicationsHepatitis C, Chronic
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Liver CirrhosisCarcinoma, Hepatocellular +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG